Literature DB >> 11150482

Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease.

N Sasaki1, S Toki, H Chowei, T Saito, N Nakano, Y Hayashi, M Takeuchi, Z Makita.   

Abstract

Advanced glycation end products (AGE) and the receptor for AGE (RAGE) have been implicated in the chronic complications of diabetes mellitus (DM), and have been reported to play an important role in the pathogenesis of Alzheimer's disease (AD). In this study, we established a polyclonal anti-RAGE antibody, and examined the immunohistochemical localization of amyloid beta protein (Abeta), AGE, and RAGE in neurons and astrocytes from patients with AD and DM. Our anti-RAGE antibody recognized full-length RAGE (50 kd) and N-terminal RAGE (35 kd) in human brain tissue. Abeta-, AGE-, and RAGE-positive granules were identified in the perikaryon of hippocampal neurons (especially from CA3 and CA4) in all subjects. The distribution and staining pattern of these immunopositive granules showed good concordance with each antibody. In AD, most astrocytes contained both AGE-and RAGE-positive granules and their distribution was almost the same. Abeta-positive granules were less common, but Abeta-, AGE-, and RAGE-positive granules were colocalized in one part of a single astrocyte. In DM patients and control cases, AGE-and RAGE-positive astrocytes were very rare. These finding support the hypothesis that glycated Abeta is taken up via RAGE and is degraded through the lysosomal pathway in astrocytes. In addition to the presence of AGE, the process of AGE degradation and receptor-mediated reactions may contribute to neuronal dysfunction and promote the progression of AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150482     DOI: 10.1016/s0006-8993(00)03075-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  70 in total

1.  Glial protein S100B modulates long-term neuronal synaptic plasticity.

Authors:  Hiroshi Nishiyama; Thomas Knopfel; Shogo Endo; Shigeyoshi Itohara
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 3.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

Review 4.  An update on treatment and prevention strategies for Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

5.  Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.

Authors:  Vladimir Volloch; Bjorn Olsen; Sophia Rits
Journal:  Ann Integr Mol Med       Date:  2020

6.  RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease.

Authors:  Fang Fang; Lih-Fen Lue; Shiqiang Yan; Hongwei Xu; John S Luddy; Doris Chen; Douglas G Walker; David M Stern; Shifang Yan; Ann Marie Schmidt; John X Chen; Shirley ShiDu Yan
Journal:  FASEB J       Date:  2009-11-11       Impact factor: 5.191

7.  Significant modifications of the salivary proteome potentially associated with complications of Down syndrome revealed by top-down proteomics.

Authors:  Tiziana Cabras; Elisabetta Pisano; Caterina Montaldo; Maria Rita Giuca; Federica Iavarone; Giuseppe Zampino; Massimo Castagnola; Irene Messana
Journal:  Mol Cell Proteomics       Date:  2013-03-26       Impact factor: 5.911

8.  Accumulation of intraneuronal Abeta correlates with ApoE4 genotype.

Authors:  Ditte Z Christensen; Thomas Schneider-Axmann; Paul J Lucassen; Thomas A Bayer; Oliver Wirths
Journal:  Acta Neuropathol       Date:  2010-03-10       Impact factor: 17.088

9.  Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases.

Authors:  Lih-Fen Lue; Douglas Gordon Walker; Sandra Jacobson; Marwan Sabbagh
Journal:  Future Neurol       Date:  2009

10.  Low levels of amyloid-beta and its transporters in neonatal rats with and without hydrocephalus.

Authors:  Kelley E Deren; Jennifer Forsyth; Osama Abdullah; Edward W Hsu; Petra M Klinge; Gerald D Silverberg; Conrad E Johanson; James P McAllister
Journal:  Cerebrospinal Fluid Res       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.